Kevin R. Sayer Sells 33,359 Shares of DexCom, Inc. (NASDAQ:DXCM) Stock

DexCom, Inc. (NASDAQ:DXCM) CEO Kevin R. Sayer sold 33,359 shares of the firm’s stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $2,899,230.69. Following the sale, the chief executive officer now directly owns 319,037 shares of the company’s stock, valued at approximately $27,727,505.67. This trade represents a 9.47 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

DexCom Trading Up 1.4 %

Shares of NASDAQ:DXCM opened at $87.62 on Friday. DexCom, Inc. has a 52 week low of $62.34 and a 52 week high of $142.00. The company’s 50 day moving average is $80.22 and its two-hundred day moving average is $76.59. The company has a market cap of $34.22 billion, a PE ratio of 52.47, a P/E/G ratio of 2.23 and a beta of 1.12. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on DXCM shares. Oppenheimer cut their price objective on DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a research report on Friday, October 25th. Wells Fargo & Company boosted their price target on shares of DexCom from $90.00 to $94.00 and gave the company an “overweight” rating in a research note on Wednesday, December 11th. Robert W. Baird raised shares of DexCom from a “neutral” rating to an “outperform” rating and increased their price objective for the stock from $86.00 to $104.00 in a research report on Thursday, January 16th. StockNews.com downgraded shares of DexCom from a “buy” rating to a “hold” rating in a report on Saturday, November 2nd. Finally, Sanford C. Bernstein upped their price target on DexCom from $82.00 to $86.00 and gave the stock an “outperform” rating in a research note on Friday, October 25th. Five research analysts have rated the stock with a hold rating, twelve have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $99.29.

Hedge Funds Weigh In On DexCom

Several large investors have recently bought and sold shares of DXCM. Allworth Financial LP boosted its position in shares of DexCom by 60.9% during the 4th quarter. Allworth Financial LP now owns 1,081 shares of the medical device company’s stock worth $84,000 after acquiring an additional 409 shares in the last quarter. Principal Securities Inc. increased its stake in DexCom by 3.4% in the fourth quarter. Principal Securities Inc. now owns 4,069 shares of the medical device company’s stock valued at $316,000 after purchasing an additional 135 shares during the last quarter. Congress Asset Management Co. increased its stake in DexCom by 5,456.9% in the fourth quarter. Congress Asset Management Co. now owns 1,356,941 shares of the medical device company’s stock valued at $105,529,000 after purchasing an additional 1,332,522 shares during the last quarter. Empire Life Investments Inc. increased its stake in DexCom by 6.6% in the fourth quarter. Empire Life Investments Inc. now owns 89,263 shares of the medical device company’s stock valued at $6,942,000 after purchasing an additional 5,537 shares during the last quarter. Finally, Bank Pictet & Cie Europe AG raised its holdings in DexCom by 1.8% during the fourth quarter. Bank Pictet & Cie Europe AG now owns 111,063 shares of the medical device company’s stock worth $8,637,000 after purchasing an additional 2,010 shares in the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.